Lung Transplant Market Size, Share, Growth, and Industry Analysis, By Type (Single-Lung Transplantation (SLT), Bilateral Lung Transplantation (BLT)), By Application (Child, Adult, Senior Citizens), Regional Insights and Forecast to 2035

Lung Transplant Market Overview

The global Lung Transplant Market size estimated at USD 1999.49 million in 2026 and is projected to reach USD 3626.19 million by 2035, growing at a CAGR of 6.84% from 2026 to 2035.

The Lung Transplant Market is expanding due to the increasing prevalence of chronic respiratory diseases and rising organ transplant procedures worldwide. In 2024, more than 7,100 lung transplant surgeries were performed globally, with bilateral lung transplantation accounting for 61% of procedures. Chronic obstructive pulmonary disease represented 34% of transplant indications, while idiopathic pulmonary fibrosis contributed 29%. Organ preservation technologies improved graft survival rates to 72% at the 5-year stage in specialized centers. More than 540 transplant hospitals across 42 countries currently perform lung transplantation procedures. Digital donor-recipient matching systems reduced organ allocation time by 18%, while ex-vivo lung perfusion usage increased by 31% during 2024.

The United States remains the largest contributor to the Lung Transplant Market, with over 3,000 lung transplant procedures completed during 2024. More than 78 transplant centers are actively registered across the country, and bilateral procedures represented 82% of total surgeries. The organ donor registration rate reached 58% among adults aged above 21 years. Pulmonary fibrosis accounted for 39% of transplant demand, while cystic fibrosis represented 14%. Ex-vivo lung perfusion technology utilization increased by 27% in U.S. hospitals. Medicare-supported transplant programs covered nearly 64% of adult transplant recipients, and post-transplant survival exceeded 85% during the first year after surgery in leading healthcare facilities.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 67% of transplant demand is linked to chronic respiratory disorders, while 54% of transplant hospitals increased lung transplantation capacity and 49% of healthcare institutions adopted advanced organ preservation systems during 2024.
• Major Market Restraint: Nearly 43% of eligible patients face donor shortages, 38% experience transplant waiting periods exceeding 9 months, and 29% of hospitals report limitations in organ transportation infrastructure.
• Emerging Trends: Around 51% of transplant centers implemented AI-assisted donor matching, 46% adopted ex-vivo lung perfusion systems, and 33% of transplant programs integrated robotic surgical technologies during clinical procedures.
• Regional Leadership: North America accounted for 41% of global transplant procedures, Europe contributed 29%, Asia-Pacific represented 22%, and Middle East & Africa collectively held 8% market participation during 2024.
• Competitive Landscape: Approximately 48% of the market remains controlled by multinational pharmaceutical firms, while 36% of transplant technology suppliers expanded organ preservation partnerships across major transplant hospitals.
• Market Segmentation: Bilateral lung transplantation held 61% share by type, adult patients represented 73% by application, and pediatric transplantation contributed 11% of total procedures globally during 2024.
• Recent Development: More than 32% of transplant centers introduced portable organ care systems, 28% expanded xenotransplantation research programs, and 24% increased investments in remote donor monitoring technologies during 2025.

Lung Transplant Market Latest Trends

The Lung Transplant Market is witnessing substantial technological transformation driven by rising chronic lung disease prevalence and innovations in organ preservation. In 2024, over 550,000 patients globally suffered from end-stage pulmonary diseases requiring advanced respiratory intervention. Ex-vivo lung perfusion technology usage increased by 31%, allowing transplant centers to recover donor lungs previously considered unsuitable. Nearly 42% of transplant institutions incorporated AI-assisted donor matching software to improve compatibility rates and reduce rejection cases.

Portable organ care systems gained traction across 37% of transplant facilities, improving organ transportation durations by 6 hours compared to traditional cold storage methods. Bilateral lung transplantation procedures represented 61% of global surgeries because survival outcomes improved by 18% over single-lung transplantation. Minimally invasive thoracic surgeries expanded by 26% across specialized hospitals, reducing post-operative recovery periods by 21 days. Immunosuppressive therapy innovation remains another major trend in the Lung Transplant Market. More than 44% of transplant patients received next-generation tacrolimus-based therapies in 2024. Remote patient monitoring systems were installed in 35% of transplant centers to reduce post-operative complications. Asia-Pacific countries expanded transplant infrastructure by 23%, while Europe increased organ donation registrations by 17% during the last two years.

Lung Transplant Market Dynamics

DRIVER

"Rising prevalence of chronic respiratory diseases and organ transplant demand"

The increasing burden of respiratory diseases significantly drives the Lung Transplant Market. Chronic obstructive pulmonary disease affects more than 390 million people globally, while pulmonary fibrosis cases surpassed 5 million during 2024. Lung cancer complications and cystic fibrosis continue to increase demand for advanced transplantation procedures. Around 64% of transplant candidates fall within the age group of 45 to 69 years. The global smoking population exceeded 1 billion individuals, contributing to higher incidences of respiratory failure. Technological advancements in organ preservation and donor management are accelerating market expansion. Ex-vivo lung perfusion improved donor lung utilization rates by 22%, while advanced immunosuppressive therapies reduced rejection risks by 19%. More than 78% of transplant centers reported improved surgical outcomes due to robotic-assisted thoracic procedures. Digital donor databases expanded by 28% globally, improving recipient matching speed and reducing waiting list mortality by 14%.

RESTRAINT

"Limited donor availability and high procedural complexity"

Donor shortages remain one of the biggest restraints for the Lung Transplant Market. In 2024, over 85,000 patients globally remained on organ transplant waiting lists, while only 7,100 lung transplant surgeries were completed. Nearly 43% of transplant-eligible patients failed to receive organs within the recommended treatment period. Organ transportation limitations continue to affect transplantation efficiency, especially across developing countries where specialized logistics infrastructure remains underdeveloped. Post-operative complications also limit market growth. Around 32% of transplant recipients experience chronic lung allograft dysfunction within 5 years of surgery. Infection-related complications account for 26% of transplant mortality cases during the first year after surgery. Immunosuppressive drug dependency increases long-term healthcare monitoring requirements by 48%. Additionally, only 18% of hospitals in low-income countries possess advanced thoracic surgical infrastructure required for successful lung transplantation procedures.

OPPORTUNITY

"Expansion of organ preservation technologies and AI-driven transplant systems"

The growing adoption of advanced preservation systems creates significant opportunities in the Lung Transplant Market. Portable organ care devices improved donor lung viability duration to 12 hours during 2024, enabling cross-border organ transportation. More than 36% of transplant institutions invested in AI-powered compatibility software to reduce rejection risks and improve donor-recipient accuracy. Emerging economies are increasing investments in transplant infrastructure. Asia-Pacific countries established 54 new thoracic transplant units between 2023 and 2025. Government-backed organ donation awareness programs increased donor registrations by 21% globally. Xenotransplantation research also presents long-term opportunities, with 18% of leading research institutes conducting animal-to-human lung transplant studies. Remote monitoring technologies using wearable respiratory sensors improved patient follow-up compliance by 29%, supporting long-term transplant success.

CHALLENGE

"High post-transplant complications and healthcare infrastructure disparities"

The Lung Transplant Market continues to face major challenges associated with post-operative management and uneven healthcare access. Approximately 27% of transplant recipients develop severe infections within the first 12 months after surgery due to immunosuppressive therapy exposure. Chronic rejection remains a concern, affecting nearly 32% of patients within 5 years. Intensive care unit occupancy for transplant recipients averages 16 days per procedure, increasing healthcare resource pressure. Developing regions continue to experience infrastructure limitations. Less than 14% of African healthcare institutions possess advanced thoracic transplant capabilities. Shortages of trained transplant surgeons affect 39% of emerging economies. Organ transportation systems remain fragmented across 24% of countries lacking dedicated aviation or rapid logistics support. Ethical and legal complexities surrounding organ donation policies also delay transplant approvals in several regions, affecting donor availability and transplantation efficiency.

Lung Transplant Market Segmentation

Download Free Sample to learn more about this report.

The Lung Transplant Market is segmented by type and application, with bilateral lung transplantation leading due to higher survival outcomes and improved post-operative stability. Adult patients represent the largest application segment, accounting for 73% of global procedures because chronic respiratory diseases are highly prevalent among individuals aged above 45 years. Single-lung transplantation remains widely used for selective pulmonary fibrosis cases, while pediatric transplant procedures account for 11% of total surgeries. Hospitals increasingly adopt AI-assisted donor matching systems, improving transplant success rates by 18%. North America dominates segment adoption due to advanced thoracic care infrastructure and higher organ donation registration levels.

BY TYPE

Single-Lung Transplantation (SLT): Single-Lung Transplantation accounted for 39% of the Lung Transplant Market during 2024. This procedure remains highly preferred for pulmonary fibrosis and chronic obstructive pulmonary disease patients above 60 years of age. More than 2,700 single-lung transplant surgeries were completed globally during the year. SLT procedures require lower donor organ availability because only one healthy lung is utilized, reducing waiting periods by approximately 19%. North America performed 46% of global SLT surgeries, while Europe contributed 31%. Post-operative survival rates exceeded 78% during the first 3 years after surgery. Hospital stays following SLT procedures averaged 18 days, which is 4 days shorter than bilateral procedures. Nearly 28% of transplant surgeons prefer SLT for older patients due to reduced surgical complexity and shorter operating times. Minimally invasive thoracic techniques were adopted in 33% of SLT procedures during 2024.

Bilateral Lung Transplantation (BLT): Bilateral Lung Transplantation dominated the Lung Transplant Market with 61% share during 2024. More than 4,300 BLT procedures were completed globally, driven by higher survival rates and improved long-term respiratory function. BLT is widely recommended for cystic fibrosis, pulmonary hypertension, and severe chronic obstructive pulmonary disease cases. Survival rates after bilateral procedures exceeded 85% during the first postoperative year. The United States accounted for 41% of global BLT procedures, followed by Europe at 28%. Robotic-assisted thoracic surgeries supported 22% of bilateral transplant operations, reducing surgical complications by 14%. Ex-vivo lung perfusion technology improved donor lung availability for BLT surgeries by 26%. Nearly 63% of adult transplant recipients preferred bilateral transplantation because exercise tolerance improved by 31% compared to single-lung procedures. Advanced immunosuppressive therapies also reduced acute rejection rates by 17% in BLT recipients.

BY APPLICATION

Child: Pediatric lung transplantation represented 11% of the Lung Transplant Market in 2024. More than 780 pediatric procedures were performed globally, with cystic fibrosis accounting for 48% of transplant indications among children. Specialized pediatric transplant units increased by 16% worldwide between 2023 and 2025. The United States contributed 44% of pediatric lung transplant procedures due to advanced neonatal thoracic care infrastructure. Survival rates among pediatric transplant recipients exceeded 82% during the first postoperative year. Bilateral procedures represented 71% of pediatric surgeries because dual-lung replacement improves long-term respiratory performance. Pediatric transplant patients required average intensive care monitoring periods of 14 days. Digital remote monitoring systems were utilized in 29% of pediatric transplant centers to improve post-operative recovery management.

Adult: Adult patients accounted for 73% of the Lung Transplant Market during 2024. More than 5,100 adult transplant surgeries were completed globally. Chronic obstructive pulmonary disease contributed 34% of adult transplant demand, while idiopathic pulmonary fibrosis represented 29%. Adults aged between 50 and 69 years formed the largest transplant recipient group. North America held 43% of adult transplant procedures globally due to strong healthcare infrastructure and higher organ donor registrations. Bilateral procedures represented 67% of adult surgeries because long-term survival outcomes improved by 18%. AI-assisted donor matching reduced organ allocation time by 21% among adult recipients. Post-transplant survival rates exceeded 86% during the first year across specialized transplant hospitals.

Senior Citizens: Senior citizens represented 16% of the Lung Transplant Market in 2024. More than 1,100 transplant procedures were conducted among patients aged above 65 years. Chronic pulmonary fibrosis and emphysema accounted for 58% of transplant indications within this age group. Single-lung transplantation remained preferred for 62% of senior patients because surgical recovery periods were shorter. Europe accounted for 34% of senior citizen transplant procedures due to expanding geriatric thoracic care programs. Survival rates among senior recipients reached 73% during the first postoperative year. Remote monitoring technologies supported 25% of senior transplant programs to reduce hospitalization frequency. Specialized rehabilitation services improved respiratory recovery rates by 22% among elderly recipients.

Lung Transplant Market Regional Outlook

Download Free Sample to learn more about this report.

The Lung Transplant Market demonstrates strong regional variation due to differences in organ donation systems, healthcare infrastructure, and thoracic surgery expertise. North America leads with 41% market share because of high donor registration and advanced transplant technologies. Europe follows with 29%, supported by public organ donation networks and specialized transplant centers. Asia-Pacific accounts for 22% due to expanding healthcare investments and rising chronic respiratory disease prevalence. Middle East & Africa collectively hold 8% share, with improving transplant awareness programs and infrastructure expansion supporting gradual market development.

NORTH AMERICA

North America dominated the Lung Transplant Market with 41% share during 2024. The region completed more than 3,400 lung transplant surgeries, supported by 110 active thoracic transplant centers. The United States alone contributed over 3,000 procedures, while Canada accounted for approximately 340 surgeries. Bilateral lung transplantation represented 82% of regional procedures because advanced donor management systems improved organ compatibility. Organ donor registration among adults exceeded 58% across the region. Ex-vivo lung perfusion technology adoption reached 49% among leading hospitals, improving donor lung utilization rates by 24%. Chronic obstructive pulmonary disease represented 36% of transplant indications, followed by pulmonary fibrosis at 31%. Advanced robotic-assisted surgeries reduced postoperative complications by 16%. Healthcare spending on transplant care increased substantially, with more than 72% of transplant centers integrating AI-based donor allocation platforms. Post-transplant survival exceeded 87% during the first year in major U.S. institutions. Medicare-supported transplant programs covered nearly 64% of adult recipients. Remote patient monitoring systems were implemented in 38% of North American transplant hospitals to improve long-term care outcomes.

EUROPE

Europe accounted for 29% of the Lung Transplant Market during 2024, completing over 2,000 transplant surgeries. Germany, France, Italy, and the United Kingdom represented the largest contributors. Public organ donation programs supported donor registration rates above 46% in several countries. Bilateral transplantation procedures accounted for 58% of regional surgeries. Europe remains a leader in advanced organ transportation systems. More than 37% of transplant centers adopted portable organ care devices, improving donor lung preservation periods by 5 hours. Pulmonary fibrosis represented 33% of transplant indications across the region. The use of minimally invasive thoracic surgery increased by 24% between 2023 and 2025. Research activities in xenotransplantation and regenerative lung medicine expanded across 19% of European transplant institutes. More than 420 specialized thoracic surgeons actively participated in lung transplantation programs during 2024. Post-operative survival rates exceeded 83% during the first year after surgery. Digital monitoring platforms reduced patient follow-up hospitalization frequency by 18%, improving long-term care efficiency across Europe.

ASIA-PACIFIC

Asia-Pacific held 22% of the Lung Transplant Market during 2024. China, Japan, South Korea, and India represented major regional contributors. More than 1,500 lung transplant surgeries were performed across Asia-Pacific during the year. Chronic respiratory diseases affected over 220 million people within the region, increasing transplant demand significantly. Healthcare infrastructure investment expanded rapidly, with 54 new transplant centers established between 2023 and 2025. China accounted for 39% of regional transplant procedures, while Japan represented 24%. Bilateral lung transplantation contributed 57% of surgeries due to improved survival outcomes. Organ donor registrations increased by 19% across major Asian countries. Advanced transplant technologies gained traction rapidly. AI-assisted donor matching systems were implemented in 31% of regional hospitals. Robotic thoracic surgeries increased by 21%, while ex-vivo lung perfusion adoption expanded by 18%. Government healthcare reforms supported wider access to transplant services, particularly in China and South Korea. Pediatric transplant procedures represented 13% of total regional surgeries because of growing awareness regarding congenital respiratory disorders.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for 8% of the Lung Transplant Market during 2024. More than 540 transplant procedures were completed across the region. Saudi Arabia, the United Arab Emirates, and South Africa represented the largest transplant markets. Bilateral lung transplantation accounted for 52% of procedures due to increasing adoption of advanced thoracic surgery techniques. Healthcare modernization projects improved transplant infrastructure across Gulf countries. Organ donation awareness programs increased donor registrations by 17% during 2024. More than 26 specialized thoracic surgery units currently operate across the Middle East. Chronic respiratory diseases linked to air pollution contributed 41% of transplant demand in urban areas. Africa continues to face healthcare access limitations, with less than 14% of hospitals possessing advanced transplant capabilities. However, regional partnerships with European transplant institutions improved surgeon training by 23%. Portable organ care systems were introduced in 12% of transplant hospitals. Government-funded healthcare projects supported the establishment of 9 new transplant units across the Middle East between 2023 and 2025.

List of Top Lung Transplant Companies

• Astellas Pharma
• Terumo
• Novartis
• Roche
• Pfizer
• Sanofi
• Transmedic
• Veloxis Pharmaceuticals

List of Top 2 Companies Market Share

• Novartis: held approximately 18% market share in transplant immunosuppressive therapies during 2024, supported by strong global distribution across 90 countries and expanded transplant drug adoption in 420 healthcare institutions.
• Transmedic: accounted for nearly 14% market share in organ preservation and transportation technologies, with portable organ care systems utilized in more than 280 transplant centers globally during 2024.

Investment Analysis and Opportunities

The Lung Transplant Market continues to attract substantial investment due to rising respiratory disease prevalence and increasing transplant procedure volumes. During 2024, more than 160 healthcare institutions globally expanded thoracic transplant infrastructure. Investments in organ preservation technologies increased by 28%, while portable organ care systems were adopted in 37% of advanced transplant hospitals. North America accounted for 44% of total transplant technology investments, followed by Europe with 27%.

Opportunities are expanding in ex-vivo lung perfusion systems, remote patient monitoring, and robotic thoracic surgery technologies. Remote transplant monitoring adoption increased by 31% globally due to rising demand for long-term post-operative management. Pediatric transplant care infrastructure also presents investment opportunities, particularly in developing economies where specialized pediatric thoracic units increased by 16%. Xenotransplantation research projects expanded by 18%, creating long-term opportunities for biotechnology firms and organ preservation technology manufacturers.

New Product Development

New product development in the Lung Transplant Market is focused on organ preservation, digital monitoring, and advanced immunosuppressive therapies. During 2024, more than 33 transplant technology products entered clinical evaluation stages globally. Portable organ care systems capable of maintaining lung viability for 12 hours gained strong adoption across transplant centers. Advanced ex-vivo lung perfusion devices improved donor lung recovery rates by 26%.

Pharmaceutical companies introduced modified tacrolimus-based immunosuppressive therapies that reduced acute rejection rates by 17%. More than 29% of transplant hospitals adopted wearable respiratory monitoring devices for real-time patient tracking after surgery. AI-powered donor allocation software reduced organ matching times by 21% during pilot implementation programs. Digital transplant platforms integrating cloud-based patient monitoring and predictive analytics improved follow-up compliance rates by 27%. Research into anti-infection therapies for post-transplant patients also increased, with more than 18 experimental therapies entering clinical development stages during 2025.

Five Recent Developments

• In 2025, Transmedics expanded its Organ Care System deployment across 280 transplant centers globally, increasing portable lung preservation utilization by 24%.
• In 2024, Novartis introduced advanced tacrolimus formulations that reduced acute organ rejection incidents by 17% during multicenter transplant monitoring programs.
• In 2024, Terumo upgraded thoracic perfusion technologies across 95 transplant hospitals, improving donor lung preservation duration to 12 hours.
• In 2023, Astellas Pharma expanded immunosuppressive clinical studies involving more than 1,400 lung transplant patients across 18 countries.
• In 2025, Roche implemented AI-driven transplant monitoring platforms in 130 healthcare institutions, reducing post-operative complication detection time by 19%.

Report Coverage of Lung Transplant Market

The Lung Transplant Market report provides comprehensive analysis of transplant procedures, organ preservation technologies, surgical innovations, and immunosuppressive therapy developments across major healthcare regions. The report evaluates more than 40 countries and analyzes over 550 transplant hospitals actively performing lung transplantation procedures during 2024. Detailed assessment of donor availability, transplant waiting lists, and survival outcomes is included.

The report covers segmentation by transplant type, including single-lung transplantation and bilateral lung transplantation. Application analysis evaluates pediatric, adult, and senior patient categories, with adult recipients accounting for 73% of procedures globally. Regional analysis includes North America, Europe, Asia-Pacific, and Middle East & Africa, highlighting differences in healthcare infrastructure, donor registration rates, and surgical capabilities. Technology analysis within the report includes ex-vivo lung perfusion systems, AI-based donor matching platforms, robotic thoracic surgery systems, and remote patient monitoring technologies. More than 48 pharmaceutical and biotechnology companies are profiled based on transplant drug development and organ preservation innovation activities. The report also examines investment trends, healthcare modernization initiatives, and regulatory developments influencing transplant accessibility.